The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor cells often resist chemotherapy and radiotherapy by employing DNA repair mechanisms.
• DNA repair is crucial for cell survival following DNA damage induced by cancer treatments.
• DNA-dependent protein kinase (DNA-PK) is a key enzyme in the non-homologous end joining (NHEJ) pathway, a major DNA repair process.

Purpose of the Study:

• To explore the role of DNA repair inhibitors in sensitizing tumor cells to cancer therapies.
• To discuss the significance of DNA-dependent protein kinase (DNA-PK) as a therapeutic target.
• To review current strategies involving DNA repair inhibition for enhanced radio- and chemo-sensitization.

Main Methods:

• Literature review and discussion of existing research on DNA repair inhibitors.
• Focus on DNA-dependent protein kinase (DNA-PK) and its role in DNA double-strand break (DSB) repair.
• Evaluation of specific DNA-PK inhibitors as potential radio- and chemo-sensitizers.

Main Results:

• DNA-PK is a critical component of the NHEJ pathway, essential for repairing DNA double-strand breaks.
• Specific inhibitors targeting DNA-PK have been identified and evaluated for their sensitizing effects.
• Inhibition of DNA repair pathways, particularly through DNA-PK, can enhance the efficacy of chemotherapy and radiotherapy.

Conclusions:

• DNA repair inhibitors, especially those targeting DNA-PK, represent a promising strategy to overcome tumor resistance.
• Targeting the NHEJ pathway offers a viable approach to improve cancer treatment outcomes.
• Further investigation and clinical evaluation of these inhibitors are warranted for radio- and chemo-sensitization.